SCHEMBL2563976

SCHEMBL2563976

COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 9/20 1.00
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
HTT P42858 2/20 0.60
GRIK1 P39086 1/20 0.58
KDM4E B2RXH2 1/20 0.57
GAA P10253 3/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29560611 1.00 IGF1R (1.00) IGF1RMEN1KMT2AHTTGRIK1
SCHEMBL31060203 1.00 IGF1R (1.00) IGF1RMEN1KMT2AHTTGRIK1
SCHEMBL2556956 0.89 IGF1R (0.81) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL4302397 0.88 IGF1R (0.79) IGF1RMEN1KMT2AHTTKDM4E
SCHEMBL6588509 0.87 IGF1R (0.77) IGF1RMEN1KMT2AHTTGRIK1
SCHEMBL4855474 0.83 HTT (0.75) IGF1RMEN1KMT2AHTTKDM4E
SCHEMBL6588862 0.82 IGF1R (0.77) IGF1RMEN1KMT2AHTTNPC1
SCHEMBL6588362 0.81 IGF1R (0.71) IGF1RMEN1KMT2AHTTKDM4E
SCHEMBL6780760 0.80 HTT (0.72) IGF1RMEN1KMT2AHTTKDM4E
SCHEMBL7690789 0.80 IGF1R (0.67) IGF1RMEN1KMT2AHTTGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10799473-B2 Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2020-10-13 US claimed
US-20160000744-A1 Methods of Inhibiting IGF-1R Activation or Downtream Signalling Thereof to Reduce Radiation-Induced Cellular Senescence UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES 2016-01-07 US claimed
WO-2014137946-A1 METHODS OF INHIBITING IGF-1R ACTIVATION OR DOWNTREAM SIGNALLING THEREOF TO REDUCE RADIATION-INDUCED CELLULAR SENESCENCE THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2014-09-12 WO claimed
WO-2011133668-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-10-27 WO claimed
EP-1150977-B1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-08-25 EP claimed
US-6699879-B1 OBESITY, DIABETES, SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-02 US claimed
US-6337338-B1 INSULIN LIKE GROWTH FACTOR RECEPTOR IN MAMMALS TELIK, INC. 2002-01-08 US claimed
EP-1150977-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2001-11-07 EP claimed
WO-2000047577-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-08-17 WO claimed
WO-2000035455-A1 HETEROARYL-ARYL UREAS AS IGF-1 RECEPTOR ANTAGONISTS TELIK, INC. (US) 2000-06-22 WO claimed
US-11319376-B2 Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer REMD BIOTHERAPEUTICS, INC. (US) 2022-05-03 US disclosed
US-10799473-B2 Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2020-10-13 US disclosed
EP-3493847-A2 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER REMD Biotherapeutics, Inc. (US) 2019-06-12 EP disclosed
US-20190169300-A1 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER REMD Biotherapeutics, Inc 2019-06-06 US disclosed
US-20190160050-A1 SMALL MOLECULE INHIBITION FOR PREVENTING OR TREATING FIBROTIC DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-30 US disclosed
US-6699879-B1 OBESITY, DIABETES, SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-02 US disclosed
US-6337338-B1 INSULIN LIKE GROWTH FACTOR RECEPTOR IN MAMMALS TELIK, INC. 2002-01-08 US disclosed
EP-1150977-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2001-11-07 EP disclosed
WO-2000047577-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-08-17 WO disclosed
WO-2000035455-A1 HETEROARYL-ARYL UREAS AS IGF-1 RECEPTOR ANTAGONISTS TELIK, INC. (US) 2000-06-22 WO disclosed